The the round saw participation from existing investors Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC, as well as new investor Conduit Connect. The full Series A round is expected to close later this year. This follows a £1.5m pre-Series A round in mid-2025 from the existing investor group.

Bioliberty, which emerged from the University of Edinburgh, develops technology that supports physical rehabilitation for the increasing number of people recovering from mobility-limiting conditions or injuries.

The platform combines AI with soft‑robotic wearable devices to help therapists deliver higher‑intensity therapy while capturing clear, objective data on patient recovery. This approach makes therapy more efficient, helps accelerate progress, and gives clinical teams the visibility they need to make more informed decisions and coordinate care more effectively.

The funding will support continued product development and manufacturing in Scotland and will enable further commercial expansion in the United States, where the company’s technology is already used in several leading rehabilitation facilities.

Rowan Armstrong, co‑founder and chief executive officer of Bioliberty, said: “This investment allows us to significantly expand our capabilities, from advancing how we measure patient recovery using computer vision and AI‑driven assessments, to extending our product into patients’ homes.

“Scotland has provided a strong foundation for Bioliberty, offering access to world‑class engineering talent and a highly collaborative research environment. This funding will enable us to grow our team in Scotland, create high‑value jobs, and continue building technology here that supports better rehabilitation outcomes.”

Bioliberty is headquartered at The National Robotarium in Edinburgh, the UK’s centre for robotics and artificial intelligence research, with manufacturing based in Fife. The company opened its U.S. headquarters in Boston in 2025, supporting its international operations while maintaining core product development activity in Scotland.

Ailsa Young, investment director at the Bank, said: “Bioliberty’s founders are ambitious, talented, and have developed an impressive solution to meet the needs of patients against the backdrop of rising healthcare costs and a strain on delivery.

“Our investment in this IP-rich company aligns to our innovation mission, helping Bioliberty to scale its technology internationally and further strengthen its home-grown excellence in robotics and AI. Critically, their products and solutions deliver tangible benefits to patients.

“We are pleased to help them scale their rollout and to help solidify Scotland’s healthtech and AI expertise, building on our recognised engineering heritage and research excellence.”

Shaolei McKie, Senior Investment Manager, Archangels said: “Archangels has supported Bioliberty, alongside our syndicate partners, since early 2023 through its initial product development and early commercialisation. The founding team has developed technology with genuine clinical value and real potential to scale into global markets, and they have consistently executed against a clear plan. We are excited to work with Scottish National Investment Bank and new investors to help deliver the next phase of growth for the company.”

The Bank is Scotland’s development bank and was established to invest in projects and businesses with the potential to deliver both commercial returns and societal benefits. Since its establishment in 2020, it has committed more than £1bn in capital to companies across Scotland.